羅妥木單抗
化合物
羅妥木單抗（INN：Robatumumab；開發代號：SCH 717454和MK-7454）是默克和先靈葆雅生產的單株抗體和抗腫瘤藥物。它與CD221（或稱胰島素樣生長因子1受體）結合。[1]
| 單株抗體 | |
|---|---|
| 種類 | 完整抗體 |
| 目標 | CD221 |
| 臨床資料 | |
| ATC碼 |
|
| 識別資訊 | |
| CAS號 | 934235-44-6  |
| ChemSpider |
|
| UNII | |
| KEGG | |
| 化學資訊 | |
| 化學式 | C6418H9960N1732O1992S42 |
| 摩爾質量 | 144,602.93 g·mol−1 |
參考資料
編輯- ^ "robatumumab", p. 337 in: Quality Assurance and Safety of Medicines. Encrenaz C , 編. Proposed International Nonproprietary Names: List 100 (PDF). WHO Drug Information. 2008, 22 (4): 311–67 [2024-01-24]. （原始內容存檔 (PDF)於2022-01-20）.
- ^ Anderson PM, Bielack SS, Gorlick RG, Skubitz K, Daw NC, Herzog CE, et al. A phase II study of clinical activity of SCH 717454 (robatumumab) in patients with relapsed osteosarcoma and Ewing sarcoma. Pediatric Blood & Cancer. October 2016, 63 (10): 1761–70. PMC 5129487
. PMID 27362300. doi:10.1002/pbc.26087.
- ^ Clinical trial number NCT00551213 for "A Study to Determine the Activity of Robatumumab (SCH 717454, MK-7454) in Participants With Relapsed or Recurrent Colorectal Cancer (P04721, MK-7454-003)" at ClinicalTrials.gov
- ^ Robatumumab. Adis Insight. Springer Nature Switzerland AG. [2024-01-24]. （原始內容存檔於2024-01-24）.
